JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB120266

Diazoxide, KIR6.x (ATP-sensitive K+ channel) activator

Be the first to review this product! Submit a review

|

(1 Publication)

MW 230.67 Da, Purity >99%. Selective KIR6.x (KATP) activator; antihypertensive. Achieve your results faster with highly validated, pure and trusted compounds.

View Alternative Names

ABC36, ABCC8_HUMAN, ATP binding cassette sub family C (CFTR/MRP) member 8, ATP binding cassette transporter sub family C member 8 (1), ATP sensitive inward rectifier potassium channel 11, ATP-binding cassette sub-family C member 8, BIR, Beta cell inward rectifier subunit, CP2D6_HUMAN, CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, CYPIID6, Cholesterol 25-hydroxylase, Cytochrome P450 2D6, Cytochrome P450 family 2 subfamily D member 6, Cytochrome P450 family 2 subfamily D polypeptide 6, Cytochrome P450-DB1, Debrisoquine 4-hydroxylase, HHF 2, HHF1, HI, HRINS, IKATP, IRK 11, Inward rectifier K(+) channel Kir6.2, Inwardly rectifying potassium channel KIR6.2, KCNJ11, Kir 6.2, MGC133230, Microsomal monooxygenase, P450 DB1, P450C2D, PHHI, Potassium channel inwardly rectifing subfamily J member 11, Potassium channel, inwardly rectifying subfamily J member 11, Potassium inwardly rectifying channel J11, SUR1delta2, Sulfonylurea receptor (hyperinsulinemia), Sulfonylurea receptor 1, TNDM 3, TNDM2, Xenobiotic monooxygenase, flavoprotein-linked monooxygenase

1 Images
Chemical Structure - Diazoxide, KIR6.x (ATP-sensitive K+ channel) activator (AB120266)
  • Chemical Structure

Lab

Chemical Structure - Diazoxide, KIR6.x (ATP-sensitive K+ channel) activator (AB120266)

2D chemical structure image of ab120266, Diazoxide, KIR6.x (ATP-sensitive K+ channel) activator

Key facts

CAS number

364-98-7

Purity

>99%

Form

Solid

form

Molecular weight

230.67 Da

Molecular formula

C<sub>8</sub>H<sub>7</sub>ClN<sub>2</sub>O<sub>2</sub>S

PubChem

3019

Nature

Synthetic

Solubility

Soluble in DMSO to 100 mM

Biochemical name

Diazoxide

Biological description

Selective KIR6.x (KATP) activator; antihypertensive.

Canonical smiles

CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl

InChi

InChI=1S/C8H7ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-4H,1H3,(H,10,11)

InChiKey

GDLBFKVLRPITMI-UHFFFAOYSA-N

IUPAC Name

7-chloro-3-methyl-4H-1λ6,2,4-benzothiadiazine 1,1-dioxide

Properties and storage information

Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
Ambient
Appropriate long-term storage conditions
Ambient
Storage information
The product can be stored for up to 12 months

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CYP2D6 also known as Cytochrome P450 2D6 is a member of the cytochrome P450 superfamily of enzymes with an approximate mass of 55 kDa. This enzyme is mainly expressed in the liver though its presence is also detected in other tissues such as the brain. It plays an important role in the metabolism of xenobiotics including drugs by catalyzing their oxidation. Notably CYP2D6 demonstrates significant genetic polymorphism influencing individual drug responses and metabolism efficiency.
Biological function summary

CYP2D6 impacts various metabolic processes by serving as an enzyme that metabolizes approximately 25% of clinical drugs including antidepressants and antipsychotics. It forms part of the large P450 enzyme family but operates dynamically through its metabolic functions rather than as a consistent participant in stable complexes. In addition to drug metabolism CYP2D6 participates in the synthesis of cholesterol steroids and other lipids.

Pathways

CYP2D6 interacts with the drug metabolism pathway particularly affecting the metabolic fate of numerous pharmaceuticals and endogenous substrates. This enzyme contributes to the cytochrome P450 pathway which is pivotal in detoxifying chemicals and metabolizing various bioactive molecules. CYP2D6 functions alongside related cytochrome enzymes like CYP3A4 affecting the metabolism of overlapping substrates.

CYP2D6 has associations with varied pharmacogenomic responses affecting treatment for diseases such as depression and schizophrenia. People with different CYP2D6 polymorphisms may experience altered drug efficacy and side effect profiles impacting treatment outcomes. Mutations or variations in CYP2D6 activity relate to other enzymes like CYP2C19 and can modulate the risk or management of conditions linked with complex drug regimens.

Product protocols

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Brain : a journal of neurology 145:2332-2346 PubMed35134125

2022

AMPK-mediated potentiation of GABAergic signalling drives hypoglycaemia-provoked spike-wave seizures.

Applications

Unspecified application

Species

Unspecified reactive species

Kathryn A Salvati,Matthew L Ritger,Pasha A Davoudian,Finnegan O'Dell,Daniel R Wyskiel,George M P R Souza,Adam C Lu,Edward Perez-Reyes,Joshua C Drake,Zhen Yan,Mark P Beenhakker
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com